Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas. Show more

Location: 2617 Bissonnet Street, Houston, TX, 77005, United States | Website: https://www.alaunos.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

6.41M

52 Wk Range

$1.31 - $6.20

Previous Close

$3.26

Open

$3.47

Volume

91,499

Day Range

$3.10 - $3.57

Enterprise Value

7.633M

Cash

319K

Avg Qtr Burn

-956.5K

Insider Ownership

9.18%

Institutional Own.

3.59%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TCR-T targeting neoantigens Details Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.